Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Net Equity Issued and Repurchased of $2.9 million for Q1 2026, down 97.31% quarter-over-quarter from $107.6 million in Q4 2025.
Inhibikase Therapeutics (IKT) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $110.5 million (up 7.21% YoY), while the FY2025 annual figure was $107.6 million, up 4.0% from the prior year.
- Net Equity Issued and Repurchased eased to $2.9 million in Q1 2026 per IKT's latest filing, from $107.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $107.6 million in Q4 2025 and bottomed at $70.0 in Q3 2023.
- Historically, Net Equity Issued and Repurchased has averaged $20.2 million across 4 years, with a median of $1.0 million in 2023.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 22053983.85% — and 2025, when it sank 100.0%.
- Inhibikase Therapeutics' Net Equity Issued and Repurchased stood at $452.0 in 2023, then surged by 22053983.85% to $99.7 million in 2024, then climbed by 7.96% to $107.6 million in 2025, then sank by 97.31% to $2.9 million in 2026.
- Business Quant data shows IKT's Net Equity Issued and Repurchased at $2.9 million in Q1 2026, $107.6 million in Q4 2025, and $150.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 107.62 Mn |
| Dec 31, 2025 | 107.62 Mn |
| Jun 30, 2025 | 150.00 |
| Jun 30, 2025 | 150.00 |
| Dec 31, 2024 | 99.68 Mn |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 397,607.00 |
| Mar 31, 2024 | 397,607.00 |
| Dec 31, 2023 | 452.00 |
| Dec 31, 2023 | 452.00 |
| Sep 30, 2023 | 70.00 |
| Sep 30, 2023 | 70.00 |
| Jun 30, 2023 | 7.54 Mn |
| Jun 30, 2023 | 7.54 Mn |